AFP and hepatocellular carcinoma: Using a lower cut-off of 10.9 ng/mL, AFP demonstrated a sensitivity as high as 66 % for early-stage HCC in a multicenter phase II biomarker trial on 836 patients (419 with HCC and 417 with cirrhosis) (Marrero et al., 2009[104]).